CRT, ArcticDx combine in cancer risk tech pact
This article was originally published in Clinica
London, UK-based oncology specialist Cancer Research Technology (CRT) has teamed up with Canadian molecular testing firm ArcticDx in a licensing agreement for the latter’s Colo Risk test for colorectal cancer. The non-exclusive agreement will see results from genome-wide Cancer Research UK-funded studies integrated into ArcticDx’s risk assessment technology. The aim is to help healthcare professionals assess patients who might be at a higher risk of developing bowel cancer, so they may receive specific individual treatment. Toronto, Ontario-based ArcticDx will make an upfront payment to CRT, which will also receive royalties form sales of the Colo Risk test.